C3.ai rises on HHS contract despite mixed earnings, skeptic views

C3.ai shares rose nearly 2% after the US HHS chose its Agentic AI Platform to modernise nationwide health data. The news lifted sentiment following Q2 results that met expectations but drew an Underperform rating and $13 target from DA Davidson. Retail traders on Stocktwits argued the stock is undervalued and supported by heavy short interest.